Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays.

Willenbrock H, Juncker AS, Schmiegelow K, Knudsen S, Ryder LP.

Leukemia. 2004 Jul;18(7):1270-7.

PMID:
15152267
[PubMed - indexed for MEDLINE]
2.

[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].

zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.

Klin Padiatr. 2000 Jul-Aug;212(4):169-73. German.

PMID:
10994545
[PubMed - indexed for MEDLINE]
3.

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

Flotho C, Coustan-Smith E, Pei D, Iwamoto S, Song G, Cheng C, Pui CH, Downing JR, Campana D.

Blood. 2006 Aug 1;108(3):1050-7. Epub 2006 Apr 20.

PMID:
16627760
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.

Dibenedetto SP, Lo Nigro L, Mayer SP, Rovera G, Schilirò G.

Blood. 1997 Aug 1;90(3):1226-32.

PMID:
9242556
[PubMed - indexed for MEDLINE]
Free Article
5.

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, Ar K, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, Camitta BM, Reaman GH, Smith MA, Downing JR, Hunger SP, Willman CL.

Blood. 2010 Feb 18;115(7):1394-405. doi: 10.1182/blood-2009-05-218560. Epub 2009 Oct 30.

PMID:
19880498
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.

Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grümayer ER.

Leukemia. 2000 Nov;14(11):1939-43.

PMID:
11069029
[PubMed - indexed for MEDLINE]
7.

Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.

Cario G, Stanulla M, Fine BM, Teuffel O, Neuhoff NV, Schrauder A, Flohr T, Schäfer BW, Bartram CR, Welte K, Schlegelberger B, Schrappe M.

Blood. 2005 Jan 15;105(2):821-6. Epub 2004 Sep 23.

PMID:
15388585
[PubMed - indexed for MEDLINE]
Free Article
8.

Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.

Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT.

J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. Review.

PMID:
11902303
[PubMed - indexed for MEDLINE]
9.

Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.

Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.

J Clin Oncol. 2008 Jun 20;26(18):3046-50. doi: 10.1200/JCO.2008.16.1117.

PMID:
18565891
[PubMed - indexed for MEDLINE]
Free Article
10.

Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.

Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G.

Leukemia. 2008 Dec;22(12):2193-200. doi: 10.1038/leu.2008.227. Epub 2008 Aug 28.

PMID:
18754029
[PubMed - indexed for MEDLINE]
11.

Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.

Gruhn B, Hongeng S, Yi H, Hancock ML, Rubnitz JE, Neale GA, Kitchingman GR.

Leukemia. 1998 May;12(5):675-81.

PMID:
9593264
[PubMed - indexed for MEDLINE]
12.

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.

Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, Aricò M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M.

Blood. 2010 Apr 22;115(16):3206-14. doi: 10.1182/blood-2009-10-248146. Epub 2010 Feb 12.

PMID:
20154213
[PubMed - indexed for MEDLINE]
Free Article
13.

Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.

Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM, von dem Borne AE, van der Schoot CE.

Leukemia. 1995 Oct;9(10):1726-34.

PMID:
7564517
[PubMed - indexed for MEDLINE]
14.

[The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].

Zhang LP, Cheng YF, Liu GL, Lu AD, Liu YR, Wang H.

Zhonghua Er Ke Za Zhi. 2005 Jul;43(7):481-5. Chinese.

PMID:
16083543
[PubMed - indexed for MEDLINE]
15.

DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers.

Staal FJ, van der Burg M, Wessels LF, Barendregt BH, Baert MR, van den Burg CM, van Huffel C, Langerak AW, van der Velden VH, Reinders MJ, van Dongen JJ.

Leukemia. 2003 Jul;17(7):1324-32. Erratum in: Leukemia. 2004 May;18(5):1041.

PMID:
12835720
[PubMed - indexed for MEDLINE]
16.

Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.

Ciudad J, San Miguel JF, López-Berges MC, Vidriales B, Valverde B, Ocqueteau M, Mateos G, Caballero MD, Hernández J, Moro MJ, Mateos MV, Orfao A.

J Clin Oncol. 1998 Dec;16(12):3774-81.

PMID:
9850021
[PubMed - indexed for MEDLINE]
17.

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR.

Lancet. 1998 Nov 28;352(9142):1731-8.

PMID:
9848348
[PubMed - indexed for MEDLINE]
18.

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.

Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, Prentice HG, Goldstone A, Hoffbrand AV, Foroni L.

J Clin Oncol. 2002 Feb 15;20(4):1094-104.

PMID:
11844835
[PubMed - indexed for MEDLINE]
19.

A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.

Flotho C, Coustan-Smith E, Pei D, Cheng C, Song G, Pui CH, Downing JR, Campana D.

Blood. 2007 Aug 15;110(4):1271-7. Epub 2007 Apr 24.

PMID:
17456722
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.

Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Söderhäll S, Taskinen M; Nordic Society of Paediatric Haematology and Oncology.

Leukemia. 2010 Feb;24(2):345-54. doi: 10.1038/leu.2009.251. Epub 2009 Dec 10. Erratum in: Leukemia. 2010 Mar;24(3):670.

PMID:
20010622
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk